Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
- Trial name
- NCT00291356
- Testing
- GSK189075 oral tablets, GW869682 oral tablets
- Where
- 3 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in North America. The aim of this trial is to evaluate the safety of insulin detemir for the treatment of diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT01709929)
- Testing
- insulin detemir
- Where
- Canada
- Volunteers
- 2,287 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
The purpose of this study is to evaluate pulmonary function test (PFT) sub-study in interested subjects from studies MKC-TI-161, MKC-TI-162 and MKC-TI-166. 100 Type I and 100 Type II diabetics will be enrolled.
- Trial name
- NCT01201928
- Testing
- Comparator administered in parent trial, Technosphere Insulin Inhalation Powder
- Where
- 14 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mannkind Corporation
New Onset Type-1 Diabetes
Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes.
- Trial name
- NCT02005848
- Testing
- Alpha-1 Antitrypsin
- Where
- 4 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Kamada, Ltd.
Diabetes Mellitus, Type 1
Effect of Fiasp® in Type 1 Diabetes Treatment
Fiasp® is a meal-time insulin that has been available in Sweden since June 2017. This study will investigate the effectiveness of Fiasp® in treating Type 1 Diabetes Mellitus.
- Trial name
- NCT03895515
- Testing
- Fiasp®
- Where
- Sweden
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and South America. The aim of this trial is to compare the glycaemic control of insulin detemir plus insulin aspart with that of insulin NPH plus human soluble insulin in subjects with type 1…
- Trial name
- NCT01486940
- Testing
- insulin detemir, insulin aspart, insulin NPH
- Where
- 75 sites in Argentina, Croatia and 13 more
- Volunteers
- 598 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics
This trial iss conducted in Europe. The aim of this clinical trial is to evaluate the hypoglycaemic response (the response to low blood sugar) to NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT01002768
- Testing
- insulin degludec, insulin glargine
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2…
- Trial name
- NCT00309608
- Testing
- Linagliptin, Glimepiride
- Where
- 48 sites in France, Germany and 4 more
- Volunteers
- 333 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare insulin degludec and insulin aspart (IDegAsp) co-formulations with separately injected, simultaneous doses of insulin degludec (insulin 454) and insulin…
- Trial name
- NCT01868568
- Testing
- insulin degludec, insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Safety and Performance Evaluation of the SAVA Continuous Glucose Monitor for Effective Glucose Detection
The goal of this clinical trial is to evaluate the safety and performance of the SAVA Continuous Glucose Monitor across glucose ranges over a period of 15-day wear in adults over 18 years of age with Type 1 Diabetes.
- Trial name
- SPEED (NCT07679347)
- Testing
- CGM Devices
- Volunteers
- 20 people
- Sponsor
- SAVA Technologies Ltd.
Type 1 Diabetes Mellitus
Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus
Each subject will be randomly allocated to a sequence of two treatments applied at two separate dosing visits. At each dosing visit subjects will be injected with individualised doses of either BioChaperone® Combo or Humalog® Mix…
- Trial name
- NCT02514954
- Testing
- Biochaperone® Combo, Humalog® Mix25
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Adocia
Type 1 Diabetes
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
- Trial name
- SAFEGUARD (NCT07187531)
- Testing
- High Dose SAB-142, Low Dose SAB-142
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 159 people
- Sponsor
- SAb Biotherapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 1
Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes
This trial is conducted in South Africa. The aim of this trial is to investigate Long term safety of biphasic insulin aspart 30 in juveniles with type 1 diabetes previously treated in trial BIAsp-1240.
- Trial name
- NCT01486381
- Testing
- biphasic insulin aspart 30
- Where
- 2 sites in South Africa
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
Primary Objective: To assess the total metabolic effect ratios of a new insulin glargine formulation versus Lantus® Secondary Objectives: To assess the exposure ratios of a new insulin glargine formulation versus Lantus® To…
- Trial name
- NCT01195454
- Testing
- Insulin glargine (HOE901)
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of an oral contraceptive combination drug…
- Trial name
- NCT01324505
- Testing
- semaglutide, Microgyn®
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to determine if recombinant human hyaluronidase PH20 (rHuPH20) will change the exposure and action of approved insulin analogs when given by continuous subcutaneous insulin infusion (CSII) in…
- Trial name
- NCT01275131
- Testing
- Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 1
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy
The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g.
- Trial name
- NCT00790088
- Where
- 26 sites in Austria, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D.
- Trial name
- NCT07038473
- Testing
- Investigational Procedure
- Where
- 7 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Quality of Life, Burden, Dependency
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life
The use by diabetes patients of real-time Continuous Glucose Monitoring (CGM) system is becoming widespread and has changed diabetic practice. Automated closed-loop (CL) insulin therapy has come of age.
- Trial name
- IMPLIQUE (NCT04939766)
- Testing
- Activation of a closed loop device in an insulin pump device with GCM
- Volunteers
- 250 people
- Sponsor
- VitalAire
Type 1 Diabetes
Threshold Suspend in Pediatrics at Home
The study objective is to demonstrate that home use of Threshold Suspend (TS) is not associated with glycemic deterioration in pediatric patients with type 1 diabetes, as measured by change in A1C.
- Trial name
- NCT02120794
- Testing
- 530G Insulin pump
- Where
- 16 sites in United States
- Volunteers
- 194 people
- Sponsor
- Medtronic MiniMed, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.